nebulised liposomal amphotericin B
Small molecule
nebulised liposomal amphotericin B is one of 26 small molecule programs targeting Aspergillosis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Aspergillosis
#DrugCompanyPhaseTrials
1Vfend
PPrism Pharmaceuticals
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Cancidas
FFresenius Kabi Oncology Ltd.
Approved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ambisome
GileadApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- EErasmus Medical Center